

Risiken von Antipsychotika im Alter, speziell bei Demenz

Dirk K. Wolter, Wasserburg a. Inn

Literatur

1. APA. APA Work Group on Alzheimer's Disease and other Dementias; Rabins PV, Blacker D, Rovner BW, Rummans T, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. *Am J Psychiatry* 2007;164(Suppl 12):5-56.
2. Ballard C, Waite J, Birks J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. *Cochrane Database Syst Rev* 2006; CD003476.
3. Ballard C, Lana MM, Theodoulou M, Douglas S, et al.; Investigators DART AD. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). *PLoS Med* 2008;5:e76.
4. Ballard C, Hanney ML, Theodoulou M, Douglas S, et al.; for the DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. *Lancet Neurol Early Online Publication* January 2009; doi:10.1016/S1474-4422(08)70295-3.
5. Barak Y, Baruch Y, Mazeh D, Paleacu D, et al. Cardiac and cerebrovascular morbidity and mortality associated with antipsychotic medications in elderly psychiatric inpatients. *Am J Geriatr Psychiatry* 2007;15:354-6.
6. Barnett MJ, Perry PJ, Alexander B, Kaboli PJ. Risk of mortality associated with antipsychotic and other neuropsychiatric drugs in pneumonia patients. *J Clin Psychopharmacol* 2006;26:182-7.
7. Barnett MJ, Wehring H, Perry PJ. Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and non-antipsychotic users. *J Clin Psychopharmacol* 2007;27:595-601.
8. Bolton JM, Metge C, Lix L, Prior H, et al. Fracture risk from psychotropic medications: a population-based analysis. *J Clin Psychopharmacol* 2008;28:384-91.
9. Brooks JO 3rd, Chang HS, Krasnykh O. Metabolic risks in older adults receiving second-generation antipsychotic medication. *Curr Psychiatry Rep* 2009;11:33-40.
10. Burke AD, Tariot PN. Atypical antipsychotics in the elderly: a review of therapeutic trends and clinical outcomes. *Expert Opin Pharmacother* 2009;10:2407-14.
11. Carson S, McDonagh MS, Peterson K. A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioural symptoms of dementia. *J Am Geriatr Soc* 2006;54:354-61.
12. Chan MC, Chong CS, Wu AY, Wong KC, et al. Antipsychotics and risk of cerebrovascular events in treatment of behavioural and psychological symptoms of dementia in Hong Kong: a hospital-based, retrospective, cohort study. *Int J Geriatr Psychiatry* 2009;Epub ahead of print.
13. Ciranni MA, Kearney TE, Olson KR. Comparing acute toxicity of first- and second-generation antipsychotic drugs: a 10-year, retrospective cohort study. *J Clin Psychiatry* 2009;70:122-9.
14. Daiello LA. Atypical antipsychotics for the treatment of dementia-related behaviours: an update. *Med Health R I* 2007;90:191-4.
15. Dean CE, Thuras PD. Mortality and tardive dyskinesia: long-term study using the US National Death Index. *Br J Psychiatry* 2009;194:360-4.
16. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. *BMJ* 2008;337:a1227.
17. Drici MD, Priori S. Cardiovascular risks of atypical antipsychotic drug treatment. *Pharmacoeconomics Drug Saf* 2007;16:882-90.
18. Elie M, Boss K, Cole MG, McCusker J, et al. A retrospective, exploratory, secondary analysis of the association between antipsychotic use and mortality in elderly patients with delirium. *Int Psychogeriatr* 2009;21:588-92.
19. Finkel S, Kozma C, Long S, Greenspan A, et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. *Int Psychogeriatr* 2005;17:617-29.
20. Fric M, Laux G, Rao ML, Schmidmaier R, et al. Plasmaspiegel von Risperidon bei Alterspatienten mit Demenz. *Psychopharmakotherapie* 2004;11:90-4.
21. Gill SS, Rochon PA, Herrmann N, Lee PE, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. *BMJ* 2005;330:445.
22. Gill SS, Bronskill SE, Normand SL, Anderson GM, et al. Antipsychotic drug use and mortality in older adults with dementia. *Ann Intern Med* 2007;146:775-86.
23. Gründer G. Antipsychotika. In: Holsboer F, Gründer G, Benkert O (Hrsg.). *Handbuch der Psychopharmakotherapie*. Berlin: Springer, 2008:591-626.
24. Hägg S, Spigset O. Antipsychotic-induced venous thromboembolism: a review of the evidence. *CNS Drugs* 2002;16:765-76.
25. Hägg S, Bate A, Stahl M, Spigset O. Associations between venous thromboembolism and antipsychotics. A study of the WHO database of adverse drug reactions. *Drug Saf* 2008;31:685-94.
26. Hartikainen S, Rahkonen T, Kautiainen H, Sulkava R. The use of psychotropics and survival in demented elderly individuals. *Int Clin Psychopharmacol* 2005;20:227-31.
27. Haupt M, Cruz-Jentoft A, Jeste D. Mortality in elderly dementia patients treated with risperidone. *J Clin Psychopharmacol* 2006;26:566-70.
28. Haverkamp W, Deuschle M. Antipsychotikainduzierte QT-Verlängerung. *Nervenarzt* 2006;77:276-88.
29. Herrmann N, Mamdani M, Lanctôt KL. Atypical antipsychotics and risk of cerebrovascular accidents. *Am J Psychiatry* 2004;161:1113-5.
30. Hollis J, Touyz S, Grayson D, Forrester L. Antipsychotic medication dispensing and associated odds ratios of death in elderly veterans and war widows. *Aust N Z J Psychiatry* 2006;40:981-6.
31. Hollis J, Forrester L, Brodaty H, Touyz S, et al. Risk of death associated with antipsychotic drug dispensing in residential aged care facilities. *Aust N Z J Psychiatry* 2007;41:751-8.
32. Hollis J, Grayson D, Forrester L, Brodaty H, et al. Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older. *Am J Geriatr Psychiatry* 2007;15:932-41.
33. Jeste DV, Blazer D, Casey D, Meeks T, et al. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. *Neuropsychopharmacology* 2008;33:957-70.
34. Kales HC, Valenstein M, Kim HM, McCarthy JF, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. *Am J Psychiatry* 2007;164:1568-76.
35. Kisely S, Cox M, Campbell LA, Cooke C, et al. An epidemiologic study of psychotropic medication and obesity-related chronic illnesses in older psychiatric patients. *Can J Psychiatry* 2009;54:269-74.
36. Kleijer BC, van Marum RJ, Egberts AC, Jansen PA, et al. Risk of cerebrovascular

Dr. med. Dirk K. Wolter, Chefarzt Gerontopsychiatrie, Inn-Salzach-Klinikum, Gabersee 7, 83512 Wasserburg am Inn, E-Mail: Dirk.Wolter@iskl.de

- events in elderly users of antipsychotics. *J Psychopharmacol* 2008; Epub ahead of print.
37. Kleijer BC, van Marum RJ, Egberts AC, Jansen PA, et al. The course of behavioural problems in elderly nursing home patients with dementia when treated with antipsychotics. *Int Psychogeriatr* 2009;21:931–40.
 38. Knol W, van Marum RJ, Jansen PA, Souverein PC, et al. Antipsychotic drug use and risk of pneumonia in elderly people. *J Am Geriatr Soc* 2008;56:661–6.
 39. Lacut K, Le Gal G, Couturaud F, Cornily G, et al. Association between antipsychotic drugs, antidepressant drugs and venous thromboembolism: results from the EDITH case-control study. *Fundam Clin Pharmacol* 2007;21:643–50.
 40. Lange-Asschenfeldt C. Psychopharmaka bei internistischen Erkrankungen. In: Holsboer F, Gründer G, Benkert O (Hrsg.). *Handbuch der Psychopharmakotherapie*. Berlin: Springer, 2008:1072–80.
 41. Layton D, Harris S, Wilton LV, Shakir SA. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. *J Psychopharmacol* 2005;19:473–82.
 42. Lee PE, Sykora K, Gill SS, Mamdani M, et al. Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. *J Am Geriatr Soc* 2005;53:1374–9.
 43. Lee PE, Fischer HD, Rochon PA, Gill SS, et al. Published randomized controlled trials of drug therapy for dementia often lack complete data on harm. *J Clin Epidemiol* 2008;61:1152–60.
 44. Liperoti R, Gambassi G, Lapane KL, Chiang C, et al. Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. *Arch Intern Med* 2005;165:696–701.
 45. Liperoti R, Gambassi G, Lapane KL, Chiang C, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. *J Clin Psychiatry* 2005;66:1090–6.
 46. Liperoti R, Pedone C, Lapane KL, Mor V, et al. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. *Arch Intern Med* 2005;165:2677–82.
 47. Liperoti R, Onder G, Lapane KL, Mor V, et al. Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study. *J Clin Psychiatry* 2007;68:929–34.
 48. Lipscombe LL, Lévesque L, Gruneir A, Fischer HD, et al. Antipsychotic drugs and hyperglycemia in older patients with diabetes. *Arch Intern Med* 2009;169:1282–9.
 49. Mazzucco S, Cipriani A, Barbui C, Monaco S. Antipsychotic drugs and cerebrovascular events in elderly patients with dementia: a systematic review. *Mini Rev Med Chem* 2008;8:776–83.
 50. Nonino F, De Girolamo G, Gamberini L, Galdoni CA; Modena Work Group for Antipsychotics in Dementia. Survival among elderly Italian patients with dementia treated with atypical antipsychotics: observational study. *Neurol Sci* 2006;27:375–80.
 51. Percudani M, Barbui C, Fortino I, Tansella M, et al. Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. *J Clin Psychopharmacol* 2005;25:468–70.
 52. Raivio MM, Laurila JV, Strandberg TE, Tilvis RS, et al. Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: A two-year prospective study. *Am J Geriatr Psychiatry* 2007;15:416–24.
 53. Ray WA, Chung CP, Murray KT, Hall K, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. *N Engl J Med* 2009;360:225–35.
 54. Rochon PA, Normand SL, Gomes T, Gill SS, et al. Antipsychotic therapy and short-term serious events in older adults with dementia. *Arch Intern Med* 2008;168:1090–6.
 55. Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, et al.; Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) investigators. Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. *Arch Gen Psychiatry* 2007;64:1259–68.
 56. Sacchetti E, Trifirò G, Caputi A, Turrina C, et al. Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. *J Psychopharmacol* 2008;22:39–46.
 57. Sacchetti E, Turrina C, Cesana B, Mazzaglia G. Timing of stroke in elderly people exposed to typical and atypical antipsychotics: a replication cohort study after the paper of Kleijer et al. *J Psychopharmacol* 2009; Epub ahead of print.
 58. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. *CMAJ* 2007;176:627–32.
 59. Schneeweiss S, Avorn J. Antipsychotic agents and sudden cardiac death – How should we manage the risk? *N Engl J Med* 2009;360:294–6.
 60. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. *JAMA* 2005;294:1934–43.
 61. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. *Am J Geriatr Psychiatry* 2006;14:191–210.
 62. Schneider LS, Tariot PN, Dagerman KS, Davis SM, et al.; CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. *N Engl J Med* 2006;355:1525–38.
 63. Schwabe U. Arzneiverordnungen für ältere Patienten. In: Schwabe U, Paffrath D (Hrsg.). *Arzneiverordnungsreport 2008*. Berlin: Springer, 2008:923–60.
 64. Setoguchi S, Wang PS, Alan Brookhart M, Canning CF, et al. Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. *J Am Geriatr Soc* 2008;56:1644–50.
 65. Sicouri S, Antzelevitch C. Sudden cardiac death secondary to antidepressant and antipsychotic drugs. *Expert Opin Drug Saf* 2008;7:181–94.
 66. Simoni-Wastila L, Ryder PT, Qian J, Zuckerman IH, et al. Association of antipsychotic use with hospital events and mortality among medicare beneficiaries residing in long-term care facilities. *Am J Geriatr Psychiatry* 2009;17:417–27.
 67. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. *JAMA* 2005;293:596–608.
 68. Stöllberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. *Int Clin Psychopharmacol* 2005;20:243–51.
 69. Straus SM, Bleumink GS, Dieleman JP, van der Lei J, et al. Antipsychotics and the risk of sudden cardiac death. *Arch Intern Med* 2004;164:1293–7.
 70. Suh GH, Shah A. Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home. *Int Psychogeriatr* 2005;17:429–41.
 71. Takkouche B, Montes-Martínez A, Gill SS, Etminan M. Psychotropic medications and the risk of fracture: a meta-analysis. *Drug Saf* 2007;30:171–84.
 72. Trifirò G, Verhamme KM, Ziere G, Caputi AP, et al. All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. *Pharmacoepidemiol Drug Saf* 2007;16:538–44.
 73. Trifirò G, Spina E, Gambassi G. Use of antipsychotics in elderly patients with dementia: Do atypical and conventional agents have a similar safety profile? *Pharmacol Res* 2009;59:1–12.
 74. Wang PS, Schneeweiss S, Avorn J, Fischer MA, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. *N Engl J Med* 2005;353:2335–41.
 75. Wang PS, Schneeweiss S, Setoguchi S, Patrick A, et al. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. *J Clin Psychopharmacol* 2007;27:707–10.
 76. Wolter D. Risiken von Antipsychotika im Alter, speziell bei Demenzen. Eine Übersicht. *Zeitschrift für Gerontopsychologie & -psychiatrie* 2009;22:17–56.